Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

Trial Identifier: D4194R00004
Sponsor: AstraZeneca
Start Date: January 2020
Primary Completion Date: December 2024
Study Completion Date: December 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
South Korea, South Korea Bucheon-si, South Korea, South Korea
South Korea, South Korea Busan, South Korea, South Korea
South Korea, South Korea Changwon, South Korea, South Korea
South Korea, South Korea Changwon-si, South Korea, South Korea
South Korea, South Korea Cheonan, South Korea, South Korea
South Korea, South Korea Chuncheon-si, South Korea, South Korea
South Korea, South Korea Goyang-si, South Korea, South Korea
South Korea, South Korea Gwangju, South Korea, South Korea
South Korea, South Korea Iksan-si, South Korea, South Korea
South Korea, South Korea Incheon, South Korea, South Korea
South Korea, South Korea Jeju-do, South Korea, South Korea
South Korea, South Korea Jeonju-si, South Korea, South Korea
South Korea, South Korea Pohang-si, South Korea, South Korea
South Korea, South Korea Seongnam-Si, South Korea, South Korea
South Korea, South Korea Uijeongbu-si, South Korea, South Korea
South Korea, South Korea Wonju-si, South Korea, South Korea
South Korea, South Korea Yangsan-si, South Korea, South Korea